title

ABOUT US

BioValues is a financial and technology advisory firm that specializes in biotechnology, pharmaceuticals, and the healthcare markets, founded by industry experts with over twenty-five years of experience. We service Investment Banks, Hedge funds, Big Pharma and equity investors, who are seeking high ROI biotech companies, both pre-IPO as well as listed small caps.

BioValues offers consulting and valuation services with an objective to facilitate and fund the right biotech ventures. We have identified key opportunities ("finds") that have a high probability of winning and dominating the market in the next five years by virtue of their technologies, products, and services. This is going to be accomplished only by a very small fraction of the players.

BioValues has a short-list of such companies, both pre-IPO as well as listed, based on various criteria that we use to understand how the companies are positioned to bring effective therapeutic modalities to the market in a relatively short time, and their prospects with consumers in the long-term.

FOUNDER and PRESIDENT

Mark Chockalingam, Ph D, MBA is a financial economist with specialized education and training in corporate finance, equity valuation and Operations Management. Mark currently is Executive Principal, Demand Planning, LLC, which provides specialized consulting in Corporate Planning and Strategy, Market Share Analysis and Supply Chain Management for the Fortune 500 Clients. His recent work includes supply chain strategy consulting for Teva Pharmaceuticals USA, FMC, Abbot Labs, Colgate Palmolive etc. In his corporate career, he has held leadership positions with companies such as Fedex, Schering-Plough Inc, and Proctor and Gamble. Mark received his doctorate in finance from Arizona State University and is a member of the Institute of Chartered Accountants of India.

Please contact us with questions, comments or enquiries about our portfolio of services. Click here to register to receive our informative monthly biotech letter.